Abstract: A water flow deflection device attached to a side of a watercraft to enhance the watercraft's wake. The device having a narrow, elongated base with two ends and a base width, the base aligned along the side of the watercraft when the device is attached to the watercraft. A deflector attached to the base between the two ends and having a face spanning between a leading end and an opposing end, the leading end extending outwardly from the base. The deflector face having a surface area configured to deflect water and a deflector width greater than the base width. The base removably attachable to the watercraft by a plurality of suction cup assemblies, wherein a greater number of suction cup assemblies located between the first end and the leading end of the deflector than between the second end and the leading end of the deflector.

Abstract: Described herein are ENPP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with ENPP1.

Abstract: A life-saving robot includes a housing having a round ring shape, a buoyancy generator disposed at an upper portion of the housing, a thrust generator disposed at a lower portion of the housing and configured to provide propulsive force, a driver configured to provide power to the thrust generator, and a guard portion that is disposed at the lower portion of the housing and covers the thrust generator. An exterior of the life-saving robot is substantially spherical and defined by a combination of the buoyancy generator, the housing, and the guard portion.

Abstract: The present application provides bicyclic spriolactam compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

Abstract: An organic compound with an electron-transport property and low water solubility is provided. An organic compound represented by General Formula (G1-1) below is provided. At least any one of R2 to R9 is a group represented by General Formula (R-1) or (R-2); each of the other groups of R2 to R9 independently represents hydrogen, an alkyl group having 1 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, an alkoxy group having 1 to 10 carbon atoms, a substituted or unsubstituted cyclic secondary amino group having 2 to 10 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, or a substituted or unsubstituted heteroaryl group having 1 to 30 carbon atoms; ?1 represents a substituted or unsubstituted arylene group having 6 to 30 carbon atoms; n represents 1 or 2; R11 to R26 each independently represent hydrogen (including deuterium) or an alkyl group having 1 to 10 carbon atoms; and p and q each independently represent 0 or 1.

Abstract: Described herein, inter alia, are clock activators and uses thereof.

Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

Abstract: A thiol-containing compound having at least two terminal groups of formula —NH—CO—CO—NH—R1—SH where R1 is an alkylene, reaction mixtures containing the thiol-containing compound and an epoxy resin, and compositions containing a polymerized product of the reaction mixture are provided. The compositions that contain the polymerized product of the reaction mixture can be used, for example, as an adhesive or sealant.

Abstract: Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.

Abstract: The present invention relates to a process for separating at least one ?-caprolactam oligomeric compound CPO from a stream SR comprising said at least one CPO and ?-caprolactam monomeric compound CPM.

Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Abstract: Provided are compounds of Formulae (I), (II) and (III) and therapeutic use of the compounds:

Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

Abstract: Provided are a diimide derivative represented by formula I, a preparation method therefor and the use thereof. The diimide derivative has a good anti-tumor activity, and the anti-proliferative activity against various cancer cells is significantly better than those of similar compounds.

Abstract: The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

Abstract: The present invention provides an improved process for the recovery of ?-caprolactam from Nylon 6 comprising multi-component material, in particular multi-layered film. Further, the invention provides a plant configured to carry out the process of the invention, and the recovered e-caprolactam obtainable by the process of the invention that has a product carbon footprint of less than 2.5 kg CO2 equivalent per kg purified e-caprolactam (based on data originating from ecoinvent version 3.7.1; location: Europe).

Abstract: The present disclosure relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments the infection is caused by a bacteria belonging to Acinetobacter spp., Clostridium spp., Enterococcus spp., Hemophilus spp., Legionella spp., Mycobacterium spp. (tuberculous and non-tuberculous Mycobacteria), Neisseria spp., Staphylococcus spp., Streptococcus spp., Listeria monocytogenes, Moraxella catarrhalis, Bacillus spp., Bacteroides spp., Gardnerella vaginalis, Lactobacillus spp., Mobiluncus spp., Helicobacter pylori, Campylobacter jejuni, Chlamydia trachomatis and/or Toxoplasma gondii; preferably the bacterial infection is caused by S. aureus, A. baumannii, E. faecium, E. faecalis, S. epidermidis, S. pneumoniae, S. pyogenes, H. influenzae, M. abscessus, M. tuberculosis, and/or M.

Abstract: This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the a invention relates to formulations and uses of the same as a medicament.

Abstract: The present invention relates to a new type pyrazolopyrimidine compound, a composition thereof, a preparation method therefor and the use thereof as an anti-cancer drug having anti-tumor activity. The new type pyrazolopyrimidine compound has structural general formula (I) as shown below, is used as an ATR inhibitor, has a good tumor inhibition activity, high selectivity, good water solubility and low toxicity, and can be used for oral administration or intravenous injection administration.